2024-519446-67-00招募中2 期
A prospective randomized open-label phase II clinical study evaluating the efficacy and safety of zoledronic acid addition to standard therapy in patients with glioblastoma
Pauls Stradins Clinical University Hospital1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2025年2月28日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Overall Survival (OS): Time from randomization to death from any cause.
研究概览
简要总结
To evaluate whether adding zoledronic acid to standard chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with glioblastoma.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Participants who are capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form and in this protocol
- •Participants who have adequate organ function as defined by the following criteria: ANC higher than 1x 109/L, Platelet count higher than 100 x 109/L, AST and serum ALT lower than 3 times ULN, ALP lower than 3 times ULN, Hemoglobin higher than 80 g/L, Estimated creatinine clearance more than 60 mL/min and calculated per institutional guidelines, Serum bilirubin lower than 1.5 times ULN with the following exception: Participants with known Gilbert syndrome: lower than 3 times ULN
- •For women of childbearing potential: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use contraception as defined below: o Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 90 days after the final dose of zoledronic acid or temozolamide. A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the individual. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, information about the reliability of abstinence will be described in the local Informed Consent Form
- •For men assigned: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm, as defined below: o With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 90 days after the final dose of zoledronic acid or temozolamide to avoid exposing the embryo. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the individual. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of preventing drug exposure. If required per local guidelines or regulations, information about the reliability of abstinence will be described in the local Informed Consent Form.
- •Participants (females and males) who are age ≥ 18 years at the time of signing Informed Consent Form
- •IDH negative (wild type) glioblastoma
- •Participants who have multicentric (the presence of two or more tumor foci within different lobes of brain) and/or multifocal (the presence of two or more tumor foci within a single lobes of brain) glioblastoma are eligible
- •Participants must have undergone surgery or stereotactic biopsy of the glioblastoma
- •Participants must have completed concurrent radio-chemotherapy prior to randomization. A washout period of at least 28 days is required between the last chemotherapy dose and randomization
- •Participants for whom resolution of all acute toxic effects of prior anti-cancer therapy to NCI CTCAE v5.0 Grade 1 or better (except alopecia, Grade 2 or better peripheral neuropathy, arthralgia or other toxicities not considered a safety risk for the participant per the investigator’s judgment)
- •Participants who have Eastern Cooperative Oncology Group Performance (ECOG) Performance Status 0, 1 or
- •Also ECOG 3 if it is caused by irreversible neurological deficit due to glioblastoma
- •Participants who are able and willing to swallow and retain oral medication
排除标准
- •Participants who are pregnant or breastfeeding, or intending to become pregnant during the study or within 90 days after the final dose of zoledronic acid or temozolamide, or within the time period specified per local prescribing guidelines after the final dose of chemotherapy
- •Participants who have had a serious infection requiring oral or IV antibiotics within 14 days prior to screening or other clinically significant infection within 14 days prior to screening
- •Participants who have had any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes an individual's safe participation in and completion of the study
- •Participants who are unable or unwilling to comply with the requirements of the protocol in the opinion of the investigator
- •Participants who have received treatment with bisphosphonates within 2 years prior to initiation of study treatment or is currently enrolled in any other type of medical research judged by the investigator not to be scientifically or medically compatible with this study
- •Participants who have any other active malignancy
- •Participants who have relapsed glioblastoma or previous other type of glioma who has transformed to glioblastoma
- •Participants who have a known clinically significant history of liver disease consistent with Child-Pugh Class C, including hepatitis (e.g., hepatitis B virus [HBV] or hepatitis C virus [HCV]), current alcohol abuse, cirrhosis, or positive test for viral hepatitis, as defined: Active infection is defined as requiring treatment with antiviral therapy or presence of positive test results for hepatitis B (hepatitis B surface antigen and/or total hepatitis B core antibody [HBcAb]) or HCV antibody; Participants who test positive for HBcAb are eligible only if test results are also positive for hepatitis B surface antibody and polymerase chain reaction is negative for HBV DNA; Participants who are positive for HCV serology are eligible only if testing for HCV RNA is negative
- •Participants who have acute or chronic kidney failure and GFR less than 60 ml/min
- •Participants who have serious mouth and dental infections and may need a dental procedures (except dental filling) in near future
- •Participants who have level of calcium in blood less than 2 mmol/l
- •Participants who have a known allergy or hypersensitivity to any of the study drugs or any of their excipients
结局指标
主要结局
Overall Survival (OS): Time from randomization to death from any cause.
Overall Survival (OS): Time from randomization to death from any cause.
Progression-Free Survival (PFS): Time from randomization to disease progression (per RANO criteria) or death, whichever occurs first.
Progression-Free Survival (PFS): Time from randomization to disease progression (per RANO criteria) or death, whichever occurs first.
次要结局
- Objective Response Rate (ORR): Proportion of patients achieving a complete or partial response per RANO criteria.
- Duration of Response (DOR): Time from the initial response to disease progression or death in patients who respond to treatment.
- Safety and Tolerability: Incidence of adverse events (AEs), serious adverse events (SAEs), and treatment-related discontinuations, assessed according to NCI CTCAE v5.0 criteria.
研究者
Sigita Hasnere
Scientific
Pauls Stradins Clinical University Hospital
研究点 (1)
Loading locations...
相似试验
招募中
3 期
A study in newly diagnosed glioblastoma patients that aims at testing the efficacy of Optune (Tumor Treating Fields), together with temozolomide and pembrolizumab compared to Optune (Tumor Treating Fields), together with temozolomide, and placebo (ie. inactive substance)2024-513550-30-00Novocure GmbH280
招募中
1 期
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor PatientsNCT07260305Kangabio AUSTRALIA LTD PTY57
招募中
3 期
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapyAcute myeloid leukemia2025-522979-29-00Fundacion PETHEMA350
招募中
3 期
Extension Study for Participants in Studies That Include Pembrolizumab2022-501254-10-00Merck Sharp & Dohme LLC1,133
已完成
不适用
Sonazoid Enhanced LivEr Cancer Trial for Early DetectioHepatitis B virus or Hepatitis C virus related liver cirrhosisJPRN-UMIN000001612Japan Liver Oncology Group (JLOG)656